About Us

Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006 and has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection.

Oramed has an experienced management team with many years of business and pharmaceutical experience and is backed by world-class scientific experts.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of people around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier – without fear of needles.

Oramed’s oral insulin is currently in advanced Phase 3 clinical trials under the US FDA and the European EMA for the treatment of type 2 diabetes.

In addition to oral insulin, the Company’s proprietary POD™ technology can potentially be used to orally administer a number of protein-based therapies, which are currently available only via injection.

Successfully Tested Technology

Oramed has successfully tested its technology via various pre-clinical and clinical studies on its two flagship products, an orally ingestible insulin capsule, ORMD-0801, and an oral GLP-1 analog capsule, ORMD-0901.

Meet The Team

MANAGEMENT
BOARD OF DIRECTORS

Kevin Rakin

Chairman

Mr. Rakin has been an Oramed Director since 2016.

He is a Co-founder and Partner at HighCape Partners, a growth equity life sciences fund.

Previously, Mr. Rakin was the President of Regenerative Medicine at Shire plc, and served as the Chairman and Chief Executive Officer of Advanced BioHealing, Inc. from 2007 until its acquisition by Shire for $750 million in June 2011.

Leonard Sank

Director

Mr. Sank has been an Oramed director since 2007.

He is an entrepreneur and businessman, based in South Africa, who is devoted to entrepreneurial endeavors and initiatives.

Mr. Sank has over 20 years of experience in important leadership roles in building and developing businesses and he serves on the Board of Directors of several other companies in a variety of sectors.

Aviad Friedman

Director

Mr. Friedman has been an Oramed Director since 2016.

Mr. Friedman is Chief Executive Officer of Most Properties 1998 Ltd. and the Chairman of the Israel Association of Community Centers.

Mr. Friedman was the first Director General of Israel’s Ministry of Diaspora Affairs and served as personal advisor to Prime Minister Ariel Sharon.

He also served as Chief Operating Officer of one of Israel’s premier newspapers, Ma’ariv and has more than 14 years of experience serving on boards of public and private companies including Maayan Ventures, Capital Point and Rosetta Green Ltd.

Arie Mayer, Ph.D

Director

Dr. Mayer has been an Oramed director since 2019.

Dr. Mayer is the Managing Director and Chairman of the Board of Merck Life Science Israel (formerly Sigma-Aldrich Israel Ltd.) and has held that position since January 2010. He has held various roles with Sigma-Aldrich Israel Ltd. since 1995 and was instrumental in introducing and developing the Cell Culture and Molecular Biology business for Sigma Aldrich Israel.

Dr. Mayer holds a Bachelor of Science in chemistry from Hebrew University and a Ph.D. in biochemistry from Israel Institute of Technology and has publications as a main author in Science, Journal of Biological Chemistry, New Scientist and the Journal of Cell Sciences.

Nadav Kidron, Esq

Chief Executive Officer,
President & Director

Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006. 

Oramed is the first company to conduct Phase 3 trials under the FDA for oral insulin.

Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries. He co-founded Oravax Medical as a joint-venture with Oramed and Premas Biotech and currently serves as the Chairman of the Board. Oravax is dedicated to bringing an oral Covid-19 vaccine to market. He also co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI Board, and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.

Mr. Kidron holds a bachelor’s degree in law and an international master’s in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.

Miriam Kidron, Ph.D

Chief Scientific Officer & Director

Dr. Kidron serves as Chief Scientific Officer and Director of Oramed Pharmaceuticals, which she co-founded in 2006.

Dr. Kidron is a pharmacologist and biochemist, who earned her PhD in biochemistry from the Hebrew University of Jerusalem.

For close to 20 years, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah-Hebrew University Medical Center in Jerusalem, Israel, earning the Bern Schlanger Award for her work on diabetes research.

She was formerly a visiting professor at the Medical School at the University of Toronto and is a member of the American, European and Israeli Diabetes Associations.

Yadin Rozov

Director

Mr. Rozov has been an Oramed director since 2022.

Mr. Rozov is an investment professional with over twenty years of experience in capital markets, corporate finance, investment banking, and investment management with substantial experience in corporate strategy and governance and he is currently the founder and Managing Partner of Terrace Edge Ventures LLC, a financial advisory firm.

Previously, Mr. Rozov was a Partner of GoldenTree Asset Management LLC, where he also served as the Chief Executive Officer and President of Syncora Guarantee Inc. and Chief Executive Officer of Financial Guaranty UK Ltd. Additionally, he was a Partner and Managing Director at Moelis & Company where he headed the Financial Institution Advisory group. While at Moelis, Mr. Rozov helped co-found College Avenue Student Loans LLC and served on its board and co-founded Chamonix Partners Capital Management LLC. Before Moelis, Mr. Rozov was a Managing Director at UBS AG, where he was the Head of the Americas for the Repositioning Group.

Mr. Rozov earned an M.Sc. in data science from Columbia University and a bachelor’s degree with highest honors in physics and materials engineering from Rutgers University.

SCIENTIFIC ADVISORY BOARD

Roy Eldor, M.D., Ph.D.

Dr. Eldor serves as Chief Medical Advisor of Oramed Pharmaceuticals, which he joined in 2016.

Dr. Eldor is an endocrinologist, internist and researcher and is currently Director of the Diabetes Unit at the Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center.

He previously served as Principal Scientist at Merck Research Laboratories, Clinical Research – Diabetes & Endocrinology. Prior to that, he served as a senior physician in internal medicine at the Diabetes Unit in Hadassah Hebrew University Hospital, Jerusalem, Israel and the Diabetes Division at the University of Texas Health Science Center in San Antonio.

Ele Ferrannini, M.D. Ph.D.

Professor Ferrannini has had extensive training in nuclear medicine and internal medicine – specializing in diabetes studies and received a Certificate of the Educational Council for Foreign Medical Graduates from the University of Bologna.

Prof. Ferrannini served as President to the European Association for the Study of Diabetes (EASD).

Prof. Ferrannini additionally completed, cum laude, a subspecialty in Diabetes and Metabolic Diseases from the University of Torino.

Avram Hershko, M.D. Ph.D

Professor Hershko is Distinguished Professor of Biochemistry at the B. Rappaport Faculty of Medicine of the Technion.

His many honors include the Israel Prize for Biochemistry (1994), the Gardner Award (1999), the Lasker Prize for Basic Medical Research (2000), the Wolf Prize for Medicine (2001) and the Louisa Gross Horwitz Award (2001). Prof. Hershko was awarded the Nobel Prize in Chemistry (2004).

Prof. Hershko is a member of the Israel Academy of Sciences (2000) and a Foreign Associate of the US Academy of Sciences (2003).

Harold Jacob, MD

Dr. Jacob currently serves as Chief Medical Officer of NanoVibronix. Previously, Dr. Jacob was Director of Medical Affairs at Given Imaging and was instrumental in the development and launch of the Given Imaging PillcamTM.

Dr. Jacob has patented and licensed a number of medical devices. He is Board Certified in Internal Medicine and Gastroenterology and is Director of Advanced Gastrointestinal Endoscopy at Hadassah Medical Center, Jerusalem.

Alexander Fleming, MD

Dr. Fleming is Founder and Executive Chairman of Kinexum. Dr. Fleming previously held various positions at the US Food and Drug Administration in which he was responsible for the therapeutic areas of diabetes, other metabolic and endocrine disorders.

He led reviews of landmark approvals, including metformin and the first statin, insulin analog, PPAR-agonist, and growth hormone for non-GH deficiency indications. Dr. Fleming oversaw clinical review of the earliest biotech products, including human insulin.

Dr. Fleming also helped to shape FDA policies and practices related to therapeutic review and regulatory communication.

Julio Rosenstock, MD

Dr. Rosenstock is the current Director of the Dallas Diabetes Research Center at Medical City Dallas and a Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Dallas. He received his medical degree from the University of Costa Rica School of Medicine and completed Fellowships in Endocrinology and Diabetes at the Royal Postgraduate Medical School, Hammersmith Hospital, London, UK, and at the University of Texas Southwestern Medical Center.

His clinical research efforts focus on exploring novel agents and therapeutic strategies to improve glycemic control. Over the last 30 years, he has participated in hundreds of clinical trials and has had an active role in the development of new oral agents and insulin preparations acting often as a lead clinical investigator and scientific advisor.

He has authored or co-authored 296 peer-reviewed manuscripts and numerous abstracts. Dr. Rosenstock is a member of the National Board of Directors of the American Diabetes Association (ADA) and is currently an Associate Editor of Diabetes Care.

Jay Skyler, MD, MACP

Dr. Skyler is Professor of Medicine, Pediatrics & Psychology in the Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine. He previously held the position of Director of the Division of Endocrinology, Diabetes & Metabolism.

In addition, Dr. Skyler is Deputy Director of Clinical Research and Academic Programs at the Diabetes Research Institute, and an Adjunct Professor of Pediatrics at the Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver. Dr. Skyler’s research focuses on the clinical aspects of diabetes, specifically the conduct of randomized controlled clinical trials.

From 1993 until 2015, he was Chairman of the NIH (NIDDK)-sponsored Diabetes Prevention Trial – Type 1 (DPT-1) and its successor Type 1 Diabetes TrialNet, a nationwide (and global) network conducting clinical trials to prevent type 1 diabetes.

Anne Peters, MD

Dr. Peters is Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs. Dr. Peters earned her medical degree from the Pritzker School of Medicine at the University of Chicago and performed an internal medicine residency at Stanford University and an endocrinology fellowship at Cedars-Sinai Medical Center. She previously directed the clinical diabetes programs at Cedars-Sinai and UCLA. Her research has focused on testing new approaches for diagnosing and treating diabetes and developing systems of care to improve outcomes in diabetic populations.

In addition to being an investigator for more than 40 research studies, Dr. Peters has published over 200 articles, has written four books, and has given more than 500 lectures locally, nationally, and internationally. She has been on multiple guideline writing committees for the treatment of both type 1 and type 2 diabetes. She was a recipient of the ADA Outstanding Physician Clinician Award, the Bernardo Houssay Award from the National Minority Quality Forum and received a 2021 Endocrine Society Laureate Award for Public Service.

Currently, Dr. Peters is the chair of the Endocrine Society Committee on Diabetes Devices and is on the EASD/ADA Technology Safety Committee. Additionally, she is a member of the JDRF Panel on Management of Exercise in type 1 Diabetes and a member of the ABIM Endocrinology Subspecialty Board. Dr. Peters has consulted for many entities, including the FDA, Optum Rx and CVS/Caremark to help guide the development and use of treatments for diabetes.

Nadav Kidron, Esq

Chief Executive Officer, President & Director

Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006. Oramed is the first company to conduct Phase 3 trials under the FDA for oral insulin.

Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries. He co-founded Oravax Medical as a joint-venture with Oramed and Premas Biotech and currently serves as the Chairman of the Board. Oravax is dedicated to bringing an oral Covid-19 vaccine to market. He also co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI Board, and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.

Mr. Kidron holds a bachelor’s degree in law and an international master’s in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.

FOLLOW NADAV:

Miriam Kidron, Ph.D

Chief Scientific Officer & Director

Dr. Kidron serves as Chief Scientific Officer and Director of Oramed Pharmaceuticals, which she co-founded in 2006.

Dr. Kidron is a pharmacologist and biochemist, who earned her PhD in biochemistry from the Hebrew University of Jerusalem.

For close to 20 years, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah-Hebrew University Medical Center in Jerusalem, Israel, earning the Bern Schlanger Award for her work on diabetes research.

She was formerly a visiting professor at the Medical School at the University of Toronto and is a member of the American, European and Israeli Diabetes Associations.

Josh Hexter

Chief Operating and Business Officer

Mr. Hexter serves as Chief Operating and Business Officer of Oramed Pharmaceuticals. Mr. Hexter has nearly two decades of prominent leadership, business development and operations know-how, entrepreneurialism and management experience in the life science sector.

Prior to his current position, Mr. Hexter was Chief Business Officer of BrainsWay Ltd. (NASDAQ/TASE: BWAY). Previously, he served as the Chief Operating Officer of Oramed. Mr. Hexter has also served as Executive Director of Corporate In-Licensing at BioLineRx (NASDAQ/TASE: BLRX) and in the private equity and venture capital sector where he served as CEO of a VC-backed start-up. As founder and CEO of Biosensor Systems Design, Mr. Hexter was instrumental in shaping the company’s strategic focus and in forging strategic agreements with Fortune 100 companies in the areas of food safety, medical diagnostics and homeland security.

Mr. Hexter earned a bachelor’s degree from the University of Wisconsin and a master’s degree in management from Boston University.

FOLLOW JOSH:

David Silberman

Chief Financial Officer

Mr. Silberman serves as Chief Financial Officer of Oramed Pharmaceuticals.  He joined Oramed in 2021.  From 2018 until 2021, Mr. Silberman served as a Corporate Financial Planning and Analysis Director at Teva Pharmaceutical Industries Ltd., a global pharmaceutical company. From 2014 to 2018, Mr. Silberman served as Global Internal Audit Senior Manager at Teva Pharmaceutical Industries Ltd.. From 2009 to 2014, Mr. Silberman provided internal audit and risk management services in the advisory department of Grant Thornton Fahn Kanne Control Management. Prior to that, Mr. Silberman worked in the audit department of KPMG, a certified public accounting firm.

Mr. Silberman holds a DCG and a DSCG degrees from the French Ministry of Higher Education and Research and is a certified public accountant in Israel.

FOLLOW DAVID:

Michael Rabinowitz

Chief Commercial Officer

Mr. Rabinowitz serves as Chief Commercial Officer of Oramed Pharmaceuticals. He has a deep and broad track record of success from over 25 years in the life sciences serving in marketing, sales, business development, and financial leadership roles in the U.S. and globally.

Prior to his current position, Mr. Rabinowitz spent over two decades at Merck in various leadership roles. At Merck, he launched and marketed products in over 30 countries across several disease areas, including launching billion-dollar oral agents in diabetes and managing a global business. He helped build disease portfolios through licensing and acquisition, as well as establishing global strategic partnerships with healthcare leaders and innovators. He also served as the Head of Investor Relations at Merck.

Mr. Rabinowitz received his bachelor’s degree summa cum laude from Northwestern University and his master’s degree from the Carlson School of Management at the University of Minnesota. He has since attended executive classes at the Harvard Business School and the Wharton School of the University of Pennsylvania.

FOLLOW MICHAEL:

Netanel Derovan

Chief Legal Officer

Mr. Derovan serves as Chief Legal Officer of Oramed Pharmaceuticals. He is a highly accomplished executive leader, having spent over 20 years in senior legal positions.

Prior to joining Oramed, Mr. Derovan served as executive counsel, corporate and securities, in the legal department of Teva Pharmaceutical Industries Ltd., as senior counsel in the International Corporate and Securities Department of Goldfarb Seligman & Co. and as an associate attorney in the International Corporate Department at Caspi & Co.

Mr. Derovan holds an LLB degree from Bar Ilan University in Israel and he is a member of the Israeli Bar Association.

FOLLOW NETANEL:

Join our mailing list

Skip to content